Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
PF-06835919 by Pfizer for Unspecified Metabolic Disorders: Likelihood of Approval
PF-06835919 is under clinical development by Pfizer and currently in Phase II for Unspecified Metabolic Disorders. According to GlobalData, Phase...